Hard to Treat Diseases (HTDS) Sells Collagenna to Axia Group Inc. (AGIJ)

  Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (http://www.htdsmedical.com) is pleased to announce the sale of former subsidiary Collagenna Skin Care Products to Axia Group Inc. (AGIJ).

HTDS was satisfied with the performance of Collagenna, a natural health products and cosmetics company that provides anti-aging skin care solutions that visibly repair and rejuvenate on the surface, and from the inside out, by unlocking the beneficial effects of collagen. This divestiture was nonetheless completed because HTDS needed to address internal restructuring, share buyback and legal matters, and in order to focus the company's portfolio.

A source close to AGIJ commented that the company is very impressed with the revenues and prospective growth offered by Collagenna, and is excited by the opportunity to acquire the company.

The divestiture of Collagenna, plus the expected sale of Serbia-based HTDS subsidiary Slavica Biochem, will allow HTDS to concentrate on its core business, China-based vaccine distributor Shenzhen Mellow Hope.

About Mina Mar Group:

Mina Mar Group pioneered the "Go Public Free" program, the first firm to challenge the short sellers, stock bashers and repeal of the "Communication Decency Act". Visit www.minamargroup.com/ice to learn more.

Mina Mar Marketing Group, MMMG (www.minamargroup.net) offers publicly traded companies full array of services such as Investor Relations and maintenance investor awareness.

To be included in company's email database for press releases, "Friday Tips", industry updates, and company activity that may or may not be news released, please subscribe for opt-in mailer at http://www.minamargroup.com/updates.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases, Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases, Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Contacts: Investor Relations: 1-647-426-1640; www.minamargroup.net/helpdesk, Investor Relations Department Inquiry, www.minamargroup.net (IR), for (M&A) and Corporate Matters, www.minamargroup.com Hard to Treat Diseases, Inc.: [e-mail]